# EDGAR Filing Document

**Accession Number:** 0001678249
**File Stem:** 0001225208-26-002133
**Filing Date:** 2026-2
**Character Count:** 8930
**Document Hash:** adf62da9cca8c8eeb9323606ea9bbe96
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001225208-26-002133.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0001225208-26-002133

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260213

**FILED AS OF DATE**: 20260218

**DATE AS OF CHANGE**: 20260218

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Butcher Arthur C
- **CENTRAL INDEX KEY:** 0001678249

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11083
- **FILM NUMBER:** 26650610

**MAIL ADDRESS:**
- **STREET 1:** C/O BOSTON SCIENTIFIC CORPORATION
- **STREET 2:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BOSTON SCIENTIFIC CORP
- **CENTRAL INDEX KEY:** 0000885725
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 042695240
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234
- **BUSINESS PHONE:** 508-683-4000

**MAIL ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Butcher Arthur C<br><sub>(Last) (First) (Middle)</sub><br>300 BOSTON SCIENTIFIC WAY<br><sub>(Street)</sub><br>MARLBOROUGH, MA 01752-1234<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP& Grp Pres, MedSurg & APAC_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BOSTON SCIENTIFIC CORP [ BSX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-13 |  | A<sup>(1)</sup> |  | 25380 | A | $0 | 50370 | D |  |
| Common Stock | 2026-02-13 |  | A<sup>(2)</sup> |  | 25380 | A | $0 | 75750 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 2237 | A | 0<sup>(3)</sup> | 77987 | D |  |
| Common Stock | 2026-02-13 |  | F |  | 25150 | D | $74.7300 | 52837 | D |  |
| Common Stock | 2026-02-14 |  | M |  | 3173 | A | 0<sup>(3)</sup> | 56010 | D |  |
| Common Stock | 2026-02-14 |  | F |  | 1535 | D | $74.7300 | 54475 | D |  |
| Common Stock | 2026-02-16 |  | M |  | 2546 | A | 0<sup>(3)</sup> | 57021 | D |  |
| Common Stock | 2026-02-16 |  | F |  | 1229 | D | $74.7300 | 55792 | D |  |
| Common Stock |  |  |  |  |  |  |  | 13354<sup>(4)</sup> | I | By 401(k) |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(3)</sup> | 2026-02-13 |  | M |  |  | 2237 | <sup>(5)</sup> | 2029-02-13<sup>(5)</sup> | Common Stock | 2237 | $0 | 6713 | D |  |
| Restricted Stock Units | <sup>(3)</sup> | 2026-02-14 |  | M |  |  | 3173 | <sup>(6)</sup> | 2027-02-14<sup>(6)</sup> | Common Stock | 3173 | $0 | 3173 | D |  |
| Restricted Stock Units | <sup>(3)</sup> | 2026-02-16 |  | M |  |  | 2546 | <sup>(7)</sup> | 2026-02-16<sup>(7)</sup> | Common Stock | 2546 | $0 | 0 | D |  |

---

### Footnotes:

(1) On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

(2) On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

(3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

(4) Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

(5) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

(6) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

(7) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

**Signature:** /s/ Susan Thompson, Attorney-in-Fact  
**Date:** 2026-02-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**